|Description||MSC2530818 is a specific and orally available CDK8 Inhibitor with an IC50 of 2.6 nM for CDK8.|
|B0084-007722||10 mg||$249||In stock|
|Brife Description||A specific and orally available CDK8 Inhibitor (CDK8 IC50 = 2.6 nM)|
|Synonyms||MSC2530818; MSC-2530818; MSC 2530818. [(2S)-2-(4-chlorophenyl)pyrrolidin-1-yl]-(3-methyl-2H-pyrazolo[3,4-b]pyridin-5-yl)methanone; SCHEMBL17514257; s8387; AKOS032946259|
|Solubility||DMSO: ≥125 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||576.5±50.0 ℃ at 760 Torr|
MSC2530818 is a specific and orally available CDK8 Inhibitor with an IC50 of 2.6 nM for CDK8.
RO-3306 is a CDK1 inhibitor with potential anticancer activity. Treatment of growing AML cells with RO-3306 induced G2/M-phase cell cycle arrest and apoptosis ...
KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.
Kenpaullone is a potent inhibitor of CDK1/cyclin B (IC50 = 400 nM), CDK2/cyclin A (IC50 = 680 nM), CDK2/cyclin E (IC50 = 7.5 uM) and CDK5/p25 (IC50 = 850 nM). K...
AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependen...
Bohemine, structurally similar to Olomoucine and Roscovitine, is a 2,6,9-trisubstituted purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhi...
AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an eff...
ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor a...